Medication info
Sitagliptin/Metformin Extended-Release Tablet 50/500 mg

Sitagliptin/Metformin Extended-Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped extended-release film-coated tablet, convex on both sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202039 · Approved 2022.05.16 · Insurance code 649606190

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which this medicine did not dissolve completely and was excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug treatment who do not achieve adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving treatment with metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start at a dose of 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate blood glucose control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral hypoglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. When taken with dietary measures and exercise, it helps effectively improve blood glucose levels. Sitagliptin and Metformin work together to effectively manage blood sugar levels. Therefore, this medication is used to enhance blood sugar control.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which this medicine did not dissolve completely and was excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug treatment who do not achieve adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving treatment with metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start at a dose of 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate blood glucose control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral hypoglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Precautions

This medication contains two components used for diabetes treatment: Sitagliptin and Metformin. Firstly, Sitagliptin can cause severe allergic reactions or skin diseases in some patients; if such symptoms occur, discontinue use immediately and consult a doctor. Additionally, there is a risk of pancreatitis, which is inflammation of the pancreas, so if symptoms like abdominal pain or vomiting appear during use, it should be carefully monitored and the medication should be discontinued if necessary. Metformin can rarely cause a serious condition called lactic acidosis, which can lead to dangerous situations due to lactic acid accumulation in the body. Therefore, it should not be used in cases of impaired kidney function, liver disease, dehydration, or severe infections. Particularly, patients with moderate to severe renal impairment should not take this medication during conditions like acute heart failure, myocardial infarction, or sepsis. Before and after tests using iodine contrast agents, this medication should be temporarily discontinued due to risks of renal function worsening and lactic acidosis, and should only be resumed after confirming normal kidney function. This medication should not be prescribed for pregnant or nursing women, children under 18 years, or patients with certain severe metabolic conditions. While taking this medication, there is a risk of hypoglycemia or lactic acidosis due to irregular eating, intense exercise, or interactions with other drugs, so caution is needed. Regular monitoring of kidney function, blood tests, and vitamin B12 levels is advisable, and it is best to avoid alcohol consumption. Moreover, it is safe to discontinue use for a certain period before and after surgery. Symptoms of hypoglycemia may occur, so blood glucose levels should be monitored carefully, especially when taken along with other hypoglycemic agents such as insulin or sulfonylureas. If severe joint pain, skin rash, difficulty breathing, or other unusual symptoms occur, notify a doctor immediately, as these symptoms may improve after stopping the medication. In case of overdose, immediate medical attention is necessary, and some components can be removed by hemodialysis. This medication should be taken cautiously according to the patient's condition, and regular check-ups and consultations with healthcare professionals during treatment are important.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute kidney failure, rash, urticaria, cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air and moisture from entering, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bright blue, oval-shaped extended-release film-coated tablet, convex on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.